Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Harvard Bioscience, Inc.
Harvard Bioscience, Inc. News
Harvard Bioscience, Inc. Quantitative Score
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Harvard Bioscience, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Harvard Bioscience, Inc. Financials
Table Compare
Compare HBIO metrics with: | |||
|---|---|---|---|
Earnings & Growth | HBIO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | HBIO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | HBIO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | HBIO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Harvard Bioscience, Inc. Income
Harvard Bioscience, Inc. Balance Sheet
Harvard Bioscience, Inc. Cash Flow
Harvard Bioscience, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Harvard Bioscience, Inc. Executives
| Name | Role |
|---|---|
| David Sirois | Director of Corporate Accounting & SEC Reporting |
| Kathryn Flynn | Corporate Controller |
| John Duke | President, Chief Executive Officer & Director |
| Mark T. Frost | Interim Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer |
| Ryan Wallace | Senior Vice President of Global Sales |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| David Sirois | Director of Corporate Accounting & SEC Reporting | -- | ||
| Kathryn Flynn | Corporate Controller | -- | ||
| John Duke | President, Chief Executive Officer & Director | Male | 1971 | -- |
| Mark T. Frost | Interim Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer | Male | 1963 | -- |
| Ryan Wallace | Senior Vice President of Global Sales | Male | -- |
Harvard Bioscience, Inc. Insider Trades
| Date | 5 Sep |
| Name | DENELSKY STEPHEN J |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 110000 |
| Date | 5 Sep |
| Name | DENELSKY STEPHEN J |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 15 Aug |
| Name | Green James W |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 49048 |
| Date | 15 Aug |
| Name | Green James W |
| Role | Director |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 33200 |
| Date | 15 Aug |
| Name | Green James W |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 119332 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 5 Sep | DENELSKY STEPHEN J | Director | Acquired | A-Award | 110000 |
| 5 Sep | DENELSKY STEPHEN J | Director | Disposed | 0 | |
| 15 Aug | Green James W | Director | Disposed | D-Return | 49048 |
| 15 Aug | Green James W | Director | Disposed | F-InKind | 33200 |
| 15 Aug | Green James W | Director | Disposed | D-Return | 119332 |